Brigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1L
Yang, JCH Kim, HR Ahn, MJ Han, JY Hochmair, MJ Lee, KH Delmonte, A Campelo, MRG Kim, DW Felip, E
Yang, JCH
Kim, HR
Ahn, MJ
Han, JY
Hochmair, MJ
Lee, KH
Delmonte, A
Campelo, MRG
Kim, DW
Felip, E
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Yang JCH, Kim HR, Ahn M-J, Han J-Y, Hochmair MJ, Lee KH, et al. O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology. 2019;30(Supplement_6).